相关实验视频

Updated: May 16, 2025

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

优化干细胞输注时间,预防急性移植对宿主疾病

Yiwen Hou¹, Yue Wu², Yang Cao³

¹Department of Hematology, The First Affiliated Hospital of USTC, Hefei National Research Center for Physical Sciences at the Microscale, National Key Laboratory of Immune Response and Immunotherapy, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Hefei 230001, China.

|April 1, 2025

概括

在异性造血干细胞移植 (allo-HSCT) 后,早些时候注入干细胞显著减少了急性移植对宿主疾病 (aGVHD). 这种简单的干预可以通过调节IL-1α等细胞因子水平来改善患者的生存率.

科学领域:

血液学
免疫学
时间生物学

背景情况:

异构造血干细胞移植 (allo-HSCT) 是血液学疾病的重要治疗方法.
急性移植对宿主疾病 (aGVHD) 仍然是一个主要的危及生命的并发症,限制了alo-HSCT的成功.

研究的目的:

研究干细胞输注的昼夜时间对aGVHD发展的影响.
为预防GVHD确定潜在的生物标志物和治疗点.

主要方法:

基于干细胞输液时间的GVHD发病率和严重程度的分析.
研究注射时间对aGVHD的影响.
测量细胞因子水平,特别是IL-1α,以及它们与aGVHD的相关性.
在临床前模型中对IL-1α中和抗体的评估.

主要成果:

早期的干细胞输液与aGVHD的发生率和严重程度显著降低.
观察到细胞因子水平的变化,特别是IL- 1α,与aGVHD的发展有关.
在临床前研究中,给予IL- 1α中和抗体显著降低了aGVHD,并改善了生存率.

结论:

干细胞输注的每日时间是影响aGVHD结果的关键因素.
在移植后的GVHD中,IL-1α起着重要的作用.
在一天的早些时候安排alo-HSCT输液可能是预防GVHD的简单有效策略.

关键词:

一个IL-1α T细胞的反应急性移植对宿主疾病整体造血干细胞移植生物节律一致的捐赠者匹配的兄弟捐赠者干细胞输液

更多相关视频

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

相关概念视频

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

Cell-mediated Immune Responses

Cell-mediated Immune Responses

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...